The estimated Net Worth of Steven Philip Sukel is at least $115 mil dollars as of 15 December 2017. Steven Sukel owns over 1,000 units of Avalon GloboCare Corp stock worth over $115,336 and over the last 8 years Steven sold AVCO stock worth over $0.
Steven has made over 3 trades of the Avalon GloboCare Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently Steven bought 1,000 units of AVCO stock worth $2,460 on 15 December 2017.
The largest trade Steven's ever made was buying 211,415 units of Avalon GloboCare Corp stock on 1 April 2017 worth over $336,150. On average, Steven trades about 72,572 units every 86 days since 2017. As of 15 December 2017 Steven still owns at least 217,615 units of Avalon GloboCare Corp stock.
You can see the complete history of Steven Sukel stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9, SUITE 3100, FREEHOLD, NJ, 07728.
Over the last 8 years, insiders at Avalon GloboCare Corp have traded over $2,500,000 worth of Avalon GloboCare Corp stock and bought 898,876 units worth $1,418,962 . The most active insiders traders include Wenzhao Lu, Luisa Ingargiola y Steven Andrew Sanders. On average, Avalon GloboCare Corp executives and independent directors trade stock every 157 days with the average trade being worth of $446,629. The most recent stock trade was executed by Wenzhao Lu on 1 April 2020, trading 645,161 units of AVCO stock currently worth $1,000,000.
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Avalon GloboCare Corp executives and other stock owners filed with the SEC include: